Assessment of lymphocyte iNKT+/CD3+/CD161+ in blood and tumor tissue in cases of benign ovarian tumors, borderline ovarian tumors and advanced-stage ovarian carcinomas

Abstract Background This study aimed to examine the performance of the four risk of malignancy index (RMI) in discriminating borderline ovarian tumors (BOTs) and benign ovarian masses in daily clinical practice. Methods A total of 162 women with BOTs and 379 women with benign ovarian tumors diagnosed at the Second Affiliated Hospital of Harbin Medical University from January 2012 to December 2016 were enrolled in this retrospective study. Also, we classified these patients into serous borderline ovarian tumor (SBOT) and mucinous borderline ovarian tumor (MBOT) subgroup. Preoperative ultrasound findings, cancer antigen 125 (CA125) and menopausal status were reviewed. The area under the curve (AUC) of receiver operator characteristic curves (ROC) and performance indices of RMI I, RMI II, RMI III and RMI IV were calculated and compared for discrimination between benign ovarian tumors and BOTs. Results RMI I had the highest AUC (0.825, 95% CI: 0.790–0.856) among the four RMIs in BOTs group. Similar results were found in SBOT (0.839, 95% CI: 0.804–0.871) and MBOT (0.791, 95% CI: 0.749–0.829) subgroups. RMI I had the highest specificity among the BOTs group (87.6, 95% CI: 83.9–90.7%), SBOT (87.6, 95% CI: 83.9–90.7%) and MBOT group (87.6, 95% CI: 83.9–90.7%). RMI II scored the highest overall in terms of sensitivity among the BOTs group (69.75, 95% CI: 62.1–76.7%), SBOT (74.34, 95% CI: 65.3–82.1%) and MBOT (59.18, 95% CI: 44.2–73.0%) group. Conclusion Compared to other RMIs, RMI I was the best-performed method for differentiation of BOTs from benign ovarian tumors. At the same time, RMI I also performed best in the discrimination SBOT from benign ovarian tumors.

Download Full-text

Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2014.06.028 ◽

2014 ◽

Vol 211 (6) ◽

pp. 637.e1-637.e6 ◽

Cited By ~ 18

Author(s):

Sofiane Bendifallah ◽

Marcos Ballester ◽

Catherine Uzan ◽

Raffaele Fauvet ◽

Philippe Morice ◽

...

Keyword(s):

Ovarian Tumors ◽

Advanced Stage ◽

Borderline Ovarian Tumors

Download Full-text

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers

Tumor Biology ◽

10.1177/1010428317706230 ◽

2017 ◽

Vol 39 (5) ◽

pp. 101042831770623 ◽

Cited By ~ 9

Author(s):

Pawel Sadlecki ◽

Pawel Walentowicz ◽

Magdalena Bodnar ◽

Andrzej Marszalek ◽

Marek Grabiec ◽

...

Keyword(s):

Ovarian Tumors ◽

Braf V600e ◽

Low Grade ◽

Braf Gene ◽

Ovarian Carcinomas ◽

Mutation Status ◽

Fully Integrated ◽

Borderline Ovarian Tumors ◽

Ovarian Masses

Epithelial ovarian tumors are a group of morphologically and genetically heterogeneous neoplasms. Based on differences in clinical phenotype and genetic background, ovarian neoplasms are classified as low-grade and high-grade tumor. Borderline ovarian tumors represent approximately 10%–20% of all epithelial ovarian masses. Various histological subtypes of ovarian malignancies differ in terms of their risk factor profiles, precursor lesions, clinical course, patterns of spread, molecular genetics, response to conventional chemotherapy, and prognosis. The most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous borderline tumors, as well as in mucinous cancers, are mutations in BRAF and KRAS genes. The most commonly observed BRAF mutation is substitution of glutamic acid for valine in codon 600 (V600E) in exon 15. The primary aim of this study was to determine whether fully integrated, real-time polymerase chain reaction–based Idylla™ system may be useful in determination of BRAF gene mutation status in codon 600 in patients with borderline ovarian tumors and low-grade ovarian carcinomas. The study included tissue specimens from 42 patients with histopathologically verified ovarian masses, who were operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz (Poland). Based on histopathological examination of surgical specimens, 35 lesions were classified as low-grade ovarian carcinomas, and 7 as borderline ovarian tumors. Specimens with expression of BRAF V600E (VE1) protein were tested for mutations in codon 600 of the BRAF gene, using an automated molecular diagnostics platform Idylla™. Cytoplasmic immunoexpression of BRAF V600E (VE1) protein was found in three specimens: serous superficial papilloma, serous papillary cystadenoma of borderline malignancy, and partially proliferative serous cystadenoma. All specimens with the expression of BRAF V600E (VE1) protein were tested positively for BRAF V600E/E2/D mutation. No statistically significant relationship (p > 0.05) was found between the presence of BRAF V600E mutation and the probability of 5-year survival. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system Idylla™ may be also a powerful prognostic tool in subjects with newly diagnosed serous borderline tumors, identifying a subset of patients who are unlikely to progress.

Download Full-text

Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.11.024 ◽

2018 ◽

Vol 148 (1) ◽

pp. 86-90 ◽

Cited By ~ 6

Author(s):

Sonia Guleria ◽

Allan Jensen ◽

Susanne K. Kjær

Keyword(s):

Cohort Study ◽

Ovarian Tumors ◽

Borderline Ovarian Tumors ◽

Benign Ovarian Tumors

Download Full-text

Differentiation of Ovarian Cancers From Borderline Ovarian Tumors on the Basis of Evaluation of Tumor Vascularity in Multi–Row Detector Computed Tomography—Comparison With Histopathology

International Journal of Gynecological Cancer ◽

10.1097/igc.0b013e3182a80a41 ◽

2013 ◽

Vol 23 (9) ◽

pp. 1597-1602 ◽

Cited By ~ 5

Author(s):

Laretta Grabowska-Derlatka ◽

Pawel Derlatka ◽

Piotr Palczewski ◽

Anna Danska-Bidzinska ◽

Ryszard Pacho

Keyword(s):

Computed Tomography ◽

Ovarian Cancer ◽

Ovarian Tumors ◽

Borderline Tumor ◽

Tumor Vascularity ◽

Ovarian Carcinomas ◽

Borderline Ovarian Tumors ◽

Ovarian Cancers ◽

Group A ◽

Group B

ObjectiveThe aim of this study was to evaluate the feasibility of multi–detector row computed tomography (MDCT) in the differentiation between borderline ovarian tumors and ovarian cancer on the basis of tumor morphology and specific features of tumor vascularity in correlation with the results at pathology.MethodsA triphasic MDCT protocol was used for the analysis of tumor vascularity. The following features were taken into account: (1) The number of vessels in papillary projections, solid-tissue component, and septa (2 vs >2), (2) serpentine and chaotic configuration of vessels, (3) presence of microaneurysms, and (4) presence of arteriovenous microfistulas. Masses with at least 3 of 4 features were considered ovarian cancer (group A) and masses with 2 features or less as borderline tumor (group B). Radiological findings were compared with results of postoperative pathology.ResultsPathologic vessels were found in all 56 patients. Thirty-two patients were included in group A and 24 in group B. The results of pathology were as follows: in group A: 31 malignant tumors, including 31 ovarian carcinomas and 1 benign cystadenoma; in group B: 22 borderline ovarian tumors, 1 benign cystadenoma, and 1 ovarian cancer.ConclusionsMorphological evaluation of tumor vascularity in MDCT seems to be an efficient method of differentiating between borderline ovarian tumors and ovarian carcinomas. Because of a small number of cases in the current study, a further research seems justified to confirm our results. The presented MDCT-angiographic criteria showed high sensitivity (97%) and specificity (96%) in differentiation of borderline ovarian tumors and ovarian cancers as compared with pathology. The presented CT-angiographic criteria of malignancy showed an excellent interobserver agreement.

Download Full-text

Urokinase and Plasminogen Activator-Inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as A Function of Histopathological Parameters

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm.1999.007 ◽

1999 ◽

Vol 37 (1) ◽

Cited By ~ 17

Author(s):

Gerald Hoffmann ◽

Kunhard Pollow ◽

Wolfgang Weikel ◽

Hans-Joachim Strittmatter ◽

Joachim Bach ◽

...

Keyword(s):

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Ovarian Tumors ◽

Ovarian Carcinomas ◽

Ovarian Metastases ◽

Benign Ovarian Tumors ◽

Activator Inhibitor ◽

Pai 1

Download Full-text

The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors

Folia Medica ◽

10.2478/folmed-2018-0082 ◽

2019 ◽

Vol 61 (2) ◽

pp. 296-302

Author(s):

Desislava M. Bozhkova ◽

Elena G. Poryazova-Markova

Keyword(s):

Tumor Progression ◽

Epithelial Mesenchymal Transition ◽

Ovarian Tumors ◽

Benign Tumors ◽

Cell Phenotype ◽

Ovarian Carcinomas ◽

Vimentin Expression ◽

Mesenchymal Transition ◽

Benign Ovarian Tumors ◽

E Cadherin

Abstract Background: The epithelial-mesenchymal transition (EMT), which is a change in the cell phenotype from epithelial to mesenchymal morphology, is an important step in the invasion process and metastasis of ovarian carcinomas. It is known that the suppression of cell adhesion molecules such as E-cadherin and the expression of mesenchymal markers such as Vimentin are key processes in EMT. There is controversy in the literature about the EMT status of ovarian carcinomas. Aim: To investigate EMT status using immunohistochemical expression of E-cadherin in benign, primary malignant serous ovarian tumors and metastases from them in order to assess their significance in tumor progression. Materials and methods: The study included a retrospective investigation of 217 ovarian epithelial tumors. Ninety-two cases of serous ovarian tumors and metastases were examined for expression of E-cadherin. Results: In our study, the predominant histological subtype in benign ovarian tumors and carcinomas was serous (73% and 61%, respectively). 65% of benign tumors demonstrated EMT negative status. The majority of carcinomas demonstrated EMT positive status (82%), whereas negative EMT status was only observed in 18% of cases. 89% of the metastases showed EMT positive status, whereas only 11% of them showed negative EMT status. In 6 selected cases with positive EMT status we found Vimentin expression in tumor cells. Conclusion: Positive EMT status (reduced E-cadherin expression) is a characteristic of ovarian carcinomas and metastases, but not of benign serous ovarian tumors.

Download Full-text

Relationship Between Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in the Probable Diagnosis of Malignant or Borderline Ovarian Tumors

10.21203/rs.3.rs-390552/v1 ◽

2021 ◽

Author(s):

Tae Hui Yoon ◽

Eun Byeol Cho ◽

Ki Ho Seol ◽

Jung Min Ryu ◽

Youn Seok Choi

Keyword(s):

Odds Ratio ◽

Blood Count ◽

Complete Blood Count ◽

Ovarian Tumors ◽

Imaging Diagnosis ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Borderline Ovarian Tumors ◽

Benign Ovarian Tumors ◽

Probable Diagnosis

Abstract Background: The purpose of this study was to investigate whether neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can be supplementary tools to differentiate benign, borderline, and malignant ovarian tumors.Methods: This retrospective study reviewed the postoperative histopathology in patients with ovarian tumors (220 benign, 59 borderline, and 228 malignant). White blood cell, platelet, neutrophil and lymphocyte counts, percentage of neutrophils and lymphocytes, calculated NLR and PLR were analyzed between groups using complete blood count tests performed before surgery. Results: The platelet count and PLR in borderline ovarian tumors tended to be statistically close to benign ovarian tumors, while the neutrophil and lymphocyte count, NLR tended to be statistically close to malignancy. The diagnostic cut-off value of NLR for differentiating between benign and borderline was 2.42, PLR for differentiating between borderline and malignancy was 140.96. When the NLR was 2.4 or higher, the odds ratio of borderline or malignant risk was 3.264. In the case of PLR, 140 or higher, the odds ratio of malignancy was 1.916. When both PLR and NLR were above each cut-off, the sensitivity of malignancy diagnosis was 51.5%, specificity was 77.0%. Conclusions: In the case of borderline ovarian tumors, the NLR was higher than benign and similarly tend to malignancy, but the PLR was lower than malignancy and similarly tend to benign. We suggest that the NLR and PLR can be used as a supplementary tool for diagnosing benign, borderline, and malignant ovarian tumors in addition to imaging diagnosis and tumor markers such as CA125.

Download Full-text